Landles, C;
BATES, GP;
(2014)
Preclinical Experimental Therapeutics.
In: BATES, GP and Tabrizi, SJ and Jones, L, (eds.)
Huntington's Disease.
(pp. 410-461).
Oxford University Press: Oxford, UK.
Preview |
Text
Chapter 16 - Preclinical Experimental therapeutics - LJ.pdf - Accepted Version Download (659kB) | Preview |
Abstract
This chapter begins by reviewing the mammalian models of Huntington’s disease (HD) that have been developed using mice, rats, and a number of large animals, including sheep, pigs, and nonhuman primates. Analysis of these models, together with genetically engineered mice created through specific manipulations of the mouse genome, has provided considerable insights into the molecular pathogenesis of HD. The number of potential therapeutic targets that have been proposed for HD is considerable, and their preclinical evaluation in HD mouse models is being used to select targets that should be pursued in drug development programs. Hence, mouse models have been used extensively to validate therapeutic targets and in the preclinical testing of therapeutic strategies. The limitations of these studies are discussed, and best-practice approaches are highlighted. The chapter concludes with a summary of the gene therapy approaches that are being developed, including strategies to lower the levels of huntingtin.
Archive Staff Only
 |
View Item |
